Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 4/20 | 0.67 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.64 |
| ▸ | CES2 | O00748 | 11/20 | 0.61 |
| ▸ | MIF | P14174 | 2/20 | 0.60 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.54 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23753476 | 0.87 | MIF (0.75) | ABCB1DNMT1CES2MIFTXNRD1 | |
| SCHEMBL23753475 | 0.87 | MIF (0.75) | ABCB1DNMT1CES2MIFTXNRD1 | |
| SCHEMBL26411651 | 0.86 | ABCB1 (0.64) | ABCB1DNMT1CES2MIFTXNRD1 | |
| SCHEMBL23764941 | 0.86 | ABCB1 (0.64) | ABCB1DNMT1CES2MIFTXNRD1 | |
| SCHEMBL28221168 | 0.76 | CES2 (1.00) | CES2MIFCXCL12 | |
| SCHEMBL30214406 | 0.76 | CES2 (1.00) | CES2MIFCXCL12 | |
| SCHEMBL28221170 | 0.76 | CES2 (1.00) | CES2MIFCXCL12 | |
| SCHEMBL28571639 | 0.76 | CES2 (0.82) | ABCB1CES2MIFCXCL12 | |
| SCHEMBL28571641 | 0.76 | CES2 (0.82) | ABCB1CES2MIFCXCL12 | |
| SCHEMBL14937330 | 0.75 | ABCB1 (1.00) | ABCB1CES2MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398238-A1 | TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION | TEXAS CHILDREN'S HOSPITAL (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2021163585-A1 | TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION | TEXAS CHILDREN'S HOSPITAL (US) | 2021-08-19 | — | — | WO | disclosed |
| US-20210252170-A1 | TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION | TEXAS CHILDREN'S HOSPITAL (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252170-A1 | TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION | SNCA, APOL1, LPAR3 | ABCB1 1727/4885DNMT1 4452/4885CES2 2346/4885 |
| US-20230398238-A1 | TARGETED CONTRAST AGENTS FOR MRI OF ALPHA-SYNUCLEIN DEPOSITION | SNCA, APOL1, LPAR3 | ABCB1 1727/4885DNMT1 4452/4885CES2 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.